What Are the Alternatives to Mounjaro for Weight Loss?

What the trial data actually show when you put these medicines side by side

The clearest head-to-head evidence comes from SURMOUNT-5, published in the New England Journal of Medicine in 2025. Over 72 weeks, adults with obesity but without diabetes lost significantly more body weight on tirzepatide (Mounjaro) than on semaglutide 2.4mg (Wegovy) on average. NICE's appraisal of tirzepatide (TA1026, published December 2024) noted that indirect comparisons across the programme favour tirzepatide, though NICE treats that evidence with appropriate caution given differences between trial populations.

Mounjaro's SURMOUNT-1 trial (2,539 participants, 72 weeks) reported average body-weight reductions of around 20–21% at the 15mg dose. The earlier STEP 1 trial of semaglutide 2.4mg reported around 15% average loss at 68 weeks. The newer Wegovy 7.2mg dose (approved as a dedicated single-dose pen by the MHRA in April 2026) showed around 20.7% average loss over 72 weeks in its trials, which does narrow the gap considerably. No single number tells the whole story, partly because individual responses vary widely and partly because trial populations differ; these figures are averages, not promises.

For Wegovy tablets, phase 3 trial data (OASIS 4, 307 adults, 64 weeks) showed approximately 13.6% average weight loss versus around 2.4% on placebo. Among participants who adhered fully to treatment, the figure was closer to 17%. Oral semaglutide's bioavailability is lower than the injection's, which explains the difference in results, the tablet is nonetheless a clinically meaningful option, particularly for people who prefer not to inject. You can read more on the oral alternative to Mounjaro page for a fuller breakdown.

Why Mounjaro's alternatives carry different licences, and why that matters more than the brand name

A question our prescribers hear most weeks is some version of: "Can I just switch to whichever is cheapest right now?" The answer is: not without clinical review, and here's why.

Each medicine has its own MHRA-approved licence that specifies who it can be prescribed for. Mounjaro is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, and separately for type 2 diabetes management. Wegovy injection shares a similar BMI threshold for weight management but the 7.2mg pen specifically requires a BMI of 30 or above; the lower 27–29.9 BMI band with a comorbidity does not apply to that particular format. Wegovy tablets are licensed for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition, the broadest coverage of the oral option.

What this means in practice is that the same person might be eligible for all three on paper, but the prescriber will look at the full picture: existing conditions (obstructive sleep apnoea, high blood pressure, dyslipidaemia, type 2 diabetes all affect the conversation), any medicines already being taken, and whether there are contraindications specific to one agent. Switching between Mounjaro and a semaglutide-based alternative, or vice versa, also requires clinical review, it isn't as straightforward as swapping one brand for another. Our Mounjaro alternatives overview goes into the eligibility picture in more detail.

If you're considering what medicine might suit you before speaking to a prescriber, our guide to alternatives to Mounjaro covers the key options and how they differ. If you're thinking about cost alongside clinical fit, the Mounjaro cost page explains what private treatment pricing typically includes and what to watch for when comparing providers.

The medicines often confused with weight-loss alternatives, Ozempic, Rybelsus and Saxenda

Search results for Mounjaro alternatives regularly surface Ozempic and Rybelsus. Both contain semaglutide, but both are licensed in the UK for type 2 diabetes, not for weight management. Prescribing either one for weight loss alone would be off-label; the MHRA is clear that GLP-1 medicines are assessed for specific indications, and diabetes medicines are not a substitute for weight-management licences. If a source suggests obtaining Ozempic or Rybelsus for weight loss without a diabetes diagnosis, that is a red flag worth taking seriously.

Saxenda (liraglutide injection, once-daily) does hold a UK weight-management licence, but it delivers smaller average weight loss than either Mounjaro or Wegovy and requires a daily rather than weekly injection. It is not something nume dispenses; it is mentioned here because it appears in searches and it is worth understanding how it fits (or doesn't) into the current landscape.

For a structured side-by-side view of how the currently licensed options compare across results, injection frequency and eligibility, the licensed weight-loss alternatives guide is worth reading before your consultation. You might also find the clinical perspective on Mounjaro alternatives useful if supply has been a factor in your search.

How a prescriber works through which option is right for you

The honest answer is that no comparison article (including this one) can replace a clinical assessment. What it can do is make that conversation more informed. A prescriber working through your consultation will typically weigh: your BMI and how much weight loss is clinically indicated; any weight-related conditions you have (which may actually point toward one medicine over another); your current medication list, since absorption interactions are relevant for tirzepatide in particular for those on oral contraceptives; your preference on injection versus tablet; and your history if you've tried one of these medicines before.

The NHS routes to Wegovy and Mounjaro both involve strict eligibility criteria and, for many people, significant waiting lists, particularly for Wegovy, which under NICE TA875 is recommended only within specialist weight management services. Private prescribing through a regulated pharmacy is one route people take when they either don't meet the NHS thresholds yet or prefer not to wait. If you'd like to explore what's available and whether you're eligible, check your eligibility with our prescribers, the consultation is free, and a GPhC-registered Independent Prescriber reviews every application personally. Our weight-loss treatment overview also sets out the options clearly if you want a broader starting point.